Ventilation strategies for Status Asthmaticus

Acute status asthmaticus is a fragile thing which, most ICU specialists would agree, is a good reason to get out of bed and drive to the hospital. These people tend to die rather readily, typically of cardiac arrest due to dynamic hyperinflation and the resulting loss of preload. This is made worse by the fact that the excellent outpatient management of asthma has filtered out the mild and moderate patient groups, and left only the incredibly brittle severe asthmatics. Only these are the people who ever get admitted to ICU for mechanical ventilation. Thankfully, even the ICU management of these people is improving, and in spite of an overall worsening severity of their illness, their ICU mortality has been steadily improving.

Severe asthma is very popular with the CICM examiners. Past paper SAQs on this topic include the following:

In brief summary, the management of severe asthma can be compressed into a short grey box:

Ventilation strategy

  • Use the largest tube possible.
  • FiO2 : lowest required to achieve SpO2 of 90-92%
  • Tidal volume: small, protective 5-7ml/kg
  • Respiratory rate: slow, 10-12 breaths per minute (or even less!)
  • Use a long expiratory time, with I:E ratio 1:3 or 1:4
  • Use a volume-controlled mode, or any other mode with a square flow waveform (i.e. constant flow) - this decreases the peak airway pressure
  • Reset the pressure limits (i.e. ignore high peak airway pressures).  .
  • Use heavy sedation.
  • Use neuromuscular blockade.
  • Minimise the duration of neuromuscular blockade.
  • Use minimal PEEP when the patient is paralysed, and titrate PEEP to work of triggering once the patient is breathing spontaneously.
  • Keep the Pplat below 25cmH2o to prevent dynamic hyperinflation. 

First-tier therapies with strong supporting evidence

  • Humidified oxygen titrated to SpO2 90-92%
  • Nebulised beta-agonist bronchodilators
  • Nebulised anticholinergic drugs
  • Steroids: IV hydrocortisone or oral prednisone

Second-tier therapies with weak supporting evidence

  • Intravenous beta-agonist bronchodilators for refractory bronchospasm
  • Methylxanthines
  • Nebulised adrenaline
  • Magnesium sulfate
  • Mucolytics
  • Helium-oxygen mixture

Third-tier therapies without any supporting evidence

  • Ketamine
  • Volatile anaesthetics
  • ECMO in asthma

There are several excellent resources for this topic, though there does not appear to be any grand unifying resource to combine all the information. Oddo et al (2006)  is a good introduction into the ventilator management of this condition, which has not changed much since 2006

 

What qualifies as "severe" asthma

There is a fairly well-defined set of features which qualifies asthma as "severe".

Historical features:

  • Previous intubation
  • Frequent admissions

Examination findings:

  • Agitation or delirium
  • Use of accessory muscles
  • Intercostal recession
  • Tracheal tug
  • Silent chest
  • Cyanosis
  • Inability to speak
  • Pulsus paradoxus in excess of 15mmHg
  • Heart rate in escess of 120

Pulmonary function test data:

  • FEV1 less than 1L
  • PEFR less than 100L/min (or less than 60% predicted)

ABG data:

  • Hypercapnea and respiratory acidosis (PaCO2more than 45mmHg) is a good reliable marker.

Risk factors for ICU admission as an episode of "Severe" asthma

How do you get yourself admitted to the ICU as a severe asthmatic?

Well. There are several physiological behavioural and environmental features which seem common.

  • Underestimation of severity: "its not that bad"
  • Smoking
  • Poor treatment compliance
  • Previous treatment with bronchodilators without steroids
  • Low socioeconomic status
  • Genetic polymorphism: IL4RA 576R allele

Features which mandate immediate ICU admission

  • Respiratory arrest
  • Delirium or decreased level of consciousness
  • Arrhythmia
  • Evidence of myocardial ischaemia

...But this list is not exclusive. Its not as if you would keep a severe asthmatic puffing away in the emergency department, waiting for these features to develop.

Physiological consequences of bronchospasm

Auto-PEEP, the trapping of pressurised gas inside the chest, is repsonsible for most of the problems in acute severe asthma.

  • Dynamic hyperinflation - manifesting as Auto-PEEP - is discussed in detail elsewhere; suffice to say that (as all excessively positive intrathoracic pressure) it has unfortunate consequences for cardiac preload, and is thus viewed as a Terrible Thing. Consider the normal cardiovascular responses to positive intrathoracic pressure, and amplify them.
  • Distorted mechanics of respiration - due to hyperinflation of the chest, the normal mechanics of respiration are grossly abnormal. Consider that normally the diaphragm hangs between the ribs as a dome-shaped structure, and by contraction increases the intrathoracic volume. Consider now what would happen if this dome-like structure were to flatten.
    mechanics of diaphragmatic excursion in hyperinflation
    That flattening, which is a typical radiological feature of the asthmatic, makes is very difficult to generate a normal tidal volume. At its limits already, the poor diaphram has nowhere else to go. By expending a massive amount of effort, it can only generate a relatively small tidal volume. Oh's Manual describes this as "a severe mechanical disadvantage".
    When this pathophysiological feature takes center stage in the presentation of an asthmatic, one tends to find extremely high PaCO2 values, and a silent chest.
  • Deranged gas exchange - due to several factors. There is a V/Q mismatch, for which both the V and the Q are responsible.
    Ventilation is lacking, to be sure - some parts of the lung are not getting any air movemewnt at all, be it due to severe airway closure, or merely because the hyperinflation creates minimal air movement (as in the case of the apices).
    Perfusion is also impaired, and this is largely an Auto-PEEP associated thing. Consider that Auto-PEEP can be as high as 30-35 cm H2O - this is pressure which directly opposes pulmonary perfusion. Consequently, the areas where this Auto-PEEP is greatest will receive the least blood flow.

Humidified oxygen titrated to SpO2 90-92%

Hyperoxia, it turns out, is harmful in asthmatics - for reasons completely divorced from CO2 retention.

VQ mismatch in asthma due to hyperoxia

Consider the hyperinflated alveolus. It, sitting there full of pressurised gas, is slowly filling up with CO2, and emptying of oxygen. Its ventilation is terrible, and the normal mechanism of hypoxic vasoconstriction has intelligently diverted blood flow from this useless cavity, to collect oxygen from better ventilated regions.

Now, see what happens when you blow extra oxygen into this intermittently ventilated alveolus. Suddenly, the burst of extra oxygen reverses the hypoxic vasoconstriction, and blood is diverted away from well-ventilated regions. The well-ventilated regions will still participate in gas exchange, to be sure - but now, CO2 clearance will be impaired, because the CO2-containing blood is being diverted to regions from which expoiratory gas escape is impossible.

On top of that, there is probably some contribution from the Haldane effect, which describes the affinity of hemoglobin for CO2. In brief, hyperoxic environments degrade this carrying capacity, decreasing the exchange of CO2 at the alveolus.

Is there any evidence for the validity of these fancy theories? Yes there is. Perrin et al published a trial in Thorax which compared liberal untargeted oxygen therapy with conservative targets (for 93-95% saturation). Turns out, the liberally oxygenated patients became hypercapnic.

This phenomenon is analogous to the need for careful O2 control in patients with COPD, and elsewhere in this site there is an exploration of the empirical evidence for the changes in CO2 with excessive oxygen administration. Though data of this sort is not available for asthma, one could surmise that it would be the same sort of relationship, if not worse.

Nebulised beta-agonist bronchodilators

Even though probably less than 10% of the nebulised drug reaches the lung, salbutamol nebs are the mainstay of treatment. Whether to nebulise the drugs with a continuous flow of oxygen, or to administer via spacer - there seems to be no real difference in effectiveness.

Intravenous beta-agonist bronchodilators for refractory bronchospasm

It is generally held that IV bronchodilators should be started when it is clear the the patient is not responding to the nebulised administration, and the reason they are held in reserve is the perception that they tend to have a massive excess of adverse effects, for comparatively little clinical benefit. 

 Lactic acidosis and hypokalemia reward the overvigorous salbutamol user. The general consensus is that these should be avoided unless absolutely necessary. There is some data that (at least in children) it may have some benefit in terms of earlier discharge from the emergency department, but no such data in adults exists. Tobin (2005) gives a perspective of his time, in case the reader wants to have a look at what their fathers thought about this strategy. 

What would make them "absolutely necessary"? Well, for one, in order for nebulised bronchodilators to be effective, they would need to have access to the bronchi. A patient in a state of near-total respiratory arrest is unlikely to be moving enough air to get any mist to its site of action. In these people, IV salbutamol may be the right choice. In effect, any nebs administered to them will only be having effect by absorbing directly into the bloodstream via the oral mucosa anyway. One can identify such patients from their ABG results; continuous nebs which are well-absorbed via the bronchi and alveoli will have a substantial systemic effect and will cause a rise in the lactate, whereas pointless nebs will not. 

A contrarian would, at this stage, pipe up with the complaint that continuous nebs, landing on the face and oropharyngeal mucosa, will often still do the bronchodilator thing by systemic absorption, which for salbutamol is surprisingly good. When Salmeron et al (1994) compared the blood levels of patients receiving nebulised salbutamol, they found them to be as high as those in their IV infusion group, suggesting the IV route was completely unnecessary.

But let's say you have decided to give IV salbutamol anyway. In general we tend not to give doses higher than 10μcg/min (5-10 µg/min is the usual range, which is about 5-10ml/hr of a 6mg/100ml infusion). One important aspect of managing such patients would be not to overreact to their hypokalemia, which is mostly the result of intracellular redistribution. The potassium level should be maintained by supplementation, as hypokalemia is bad for muscle (cardiac and other), but the target level should be down-adjusted. The reason for this is the post-salbutamol redistribution of potassium back into the circulation, potentially giving rise to lifethreatening rebound hyperkalemia within a couple of hours of the cessation of the infusion.

Nebulised anticholinergic drugs

Ipratropium nowadays gets used for all acute asthmatics, because of its suspected benefit, and absence of harm. The anticholinergics seem to be useless on their own, but potent in combination with beta-agonists.

Steroids: IV hydrocortisone or oral prednisone

From internship, one recalls the tendency for these asthmatic people to be put on 100mg qid of hydrocortisone, which equates to about 100mg of oral prednisolone. There are many benfits:

  • ablation of IgE-mediated inflammatory response
  • increased responsiveness of the smooth muscle to beta-2 agonists
  • decreased mucus secretion

However, it seems oral agents are at least as effective as intravenous agents, and that there is no benefit in giving truly massive doses (eg. over 800mg/day of hydrocortisone).

Methyxanthines

Aminiphylline is the only one available in Australia. Its use tends to be reserved for patients refractory to the first tier of therapies.

In general, the current opinion of aminophylline is that it ...

  • is a poor bronchodilator
  • is associated with a prohibitive toxicity
  • has a narrow therapeutic range and needs monitoring (levels should not get above 10μmol/L)

There is also an entire population of patients in whom it should never be even considered:

  • Heart failure
  • Cirrhosis
  • COPD

Additonally, aminophylline interacts with a whole host of drugs, making its use a fiddly and complicated affair. It can even decrease the sedating effects of propofol.

Not a lot of aminophylline experience exists in the modern era. Most of the time, when one comes across aminophylline in the literature, some variation of the phrase "still used in spite of".  Aralihond et al (2020) describes mostly paediatric experience, which is likely to be also representative of the adult experience.  In short, the risks and disadvantages appear to be overstated in the critical care folklore, perhaps because everyone is aware of all the possible side effects and takes active steps to mitigate them. 

So, say you decided to use this horrible stuff anyway. The British Thoracic Society recommend a loading dose of 5mg/kg, or about 350-400mg (one and a half of the 250mg-ampules), followed
by an infusion of something like 20-25mg/min. Brave souls have even used 10mg/kg as a loading dose. What would you expect, in terms of positive effects? It appears that some authors have found a trend towards improved airflow when using this drug in combination with other bronchodilators. It may have some kind of synergistic effect with β-agonists, for example.

Nebulised adrenaline

Some might say that the vasoconstricting effects of adrenaline are beneficial in asthma because they address the inflamed vascular engorgement of the bronchial lining. It may also have some kind of antihistamine effect (Baldwin et al, 1994).  In early studies, it had compared favourably. However, well-designed trials which followed had demonstrated that it is no different to salbutamol in efficacy, and that salbutamol has fewer adverse events.

IV or nebulised adrenaline is one of the things you try when you are truly stuck, and have nothing else to add to the management.

Magnesium sulfate

The use of magnesium sulfate in asthma is controversial; generally speaking everybody knows that "thats what you give for severe asthma" but when one examines the evidence, there is actually nothing to support its routine use in anything but the most desperate situations. The MAGNETIC trial has demonstrated that nebulised magneisum sulfate may actually have a little bit of benefit in children with severe asthma, and a 2013 meta-analysis has confirmed that IV magnesium has a statistically significant influence on resiratory function among adults.

Oh's Manual only gives it a lukewarm recommendation. Costello & Howes (2004) could not find support for this in their literature review, and 

Ketamine

ketamine is generally though to be a bronchodilator by a variety of mechanisms, the chief of which is probably sympathomimetic. This all sounds very nice, but the evidence for its use in adults is not very strong, and a recent meta-analysis has demonstrated that it has no benefit in acutely asthmatic children. In its support, we only have case series of questionable quality.

That said, I think nobody should die of asthma without having had a trial of ketamine.

Helium-oxygen mixture

Heliox, the trade name of the 70% helium - 30% oxygen mixture, is another measure one may consider when faced with a comletely impenetrable bronchospasm. This therapy, in contrast to such baddies as adrenaline and aminophylline, remains on the menu purely because it has so few adverse effects (and who cares about the lack of benefit, right?)

The theory behind it is well summarised in the 2006 paper by Wigmore and Stachowski. Characteristically of these authors, interesting details of physics are offered, including a table of the physical properties of gases at room temperature and pressure. One immediately notices that the density of helium is vastly lower than the density of oxygen, or all the other atmospheric gases for that matter. This leads to an improvement in the flow of gas through narrow cylinders; laminar flow occurs in tight spaces where turbulence would otherwise appen.

Thus, the benefit of this therapy lies in the decreased effort of breathing. This seems to have some benefit in the setting of severe asthma (but, as expected, the mild and moderate asthmatics get nothing out of it). Ther are really very few risks - helium is very well tolerated. The major risk is hypoxia, because the ideal mixture of gases has only 30% FiO2, and not every asthma patient can tolerate this.

Volatile anaesthetics

Like ketamine, these are only described in small case series. There is an inherent difficulty in fitting a volatile vapouriser to the ICu ventilator. That said, it seems they are potent bronchodilators, and can make all the difference in an intubated severely bronchospastic patient. In essence, this therapy should be brought into the equation as a prelude to ECMO.

Evidence for the use of non-invasive ventilation in asthma

NIV has a number of theoretical benefits in asthma:

  • Extrinsic PEEP decreases the work of breathing by helping overcome Auto-PEEP
  • Extrinsic inspiratory positive pressure (IPAP) may increase tidal volume by decreasing the work done against airway resistance
  • Shorter inspiratory times may increase tidal volumes without causing any extra dynamic hyperinflation
  • NIV may be able to prevent intubation in a selected group of patients.

NIV also has a number of theoretical disadvantages. 

  • May delay intubation
  • Inappropriate settings may increase the effort of breathing
  • Increased positive airway pressure increases risk of pneumothorax
  • Addition of extrinsic PEEP which is higher than intrinsic PEEP will exacerbate dynamic hyperinflation
  • NIV makes it more difficult to clear secretions if there is a strong infective component.

The evidence for the use of NIV in asthma is not as strong as the evidence for its use in COPD, but among the experts the general opinion is that NIV in asthma is useful. So what if there haven't been enough trials to confirm the improvement in mortality?

However, the evidence has significant limitations:

  • Trials are small, ~ 30 people! The most recent meta-analysis of such RCTs (Lim et al, 2012) ended up scraping together five studies - which only had n=206 in total.
  • The data has so far failed to demonstrate a clear mortality benefit, but this is mainly because the groups of patients enrolled into these studies have not been very sick. For an example, let us take endotracheal intubation. Of the 90-or so patients in two RCTs analysed by Lim et al, only two required intubation. There were no deaths in either group. How can you demonstrate a mortality benefit if nobody is dying?..
  • A recent systematic review by Green et al (2017) found the available studies (13 met criteria) had such heterogeneity that no recommendations could be made.

Practical use of NIV in the acute severe asthmatic

Indications for NIV in the acute asthmatic are thought to be:

  • hypercapnea
  • severe dyspnoea
  • use of accessory muscles
  • respiratory rate greater than 25

Full face masks are usually best.

No "routine" pressure settings can be recommended; it is best to stand at the bedside and adjust the pressures until the patient feels their breathing is getting easier. Oh's Manual suggests initial settings of 5cmH2O EPAP, and 8-10cmH2O of pressure support on top of this (i.e. an IPAP of 13-15 cmH2O).

Predictors of failure in using NIV for the acute severe asthmatic

If n=206 was depressing, then you're going to love this area. It seems we have only this conference abstract to work with (Samaria et al, 2011). In this n=54 prospective cohort, NIV failure was defined as the need for intubation. The following features identified patients who would go on to be intubated after a trial of NIV (as defined by an hour of continuous NIV)

  • High APACHE II score at presentation
  • High respiratory rate after 1 hour of NIV
  • Tachycardia  after 1 hours of NIV
  • persistently high CO after 1 hour of NIV

A gradual course of onset makes you think the patient will fail NIV. If the asthma attack has been going for days, the patient arrives to the ED when they are already exhausted.

When to intubate the asthmatic patient

Another way of asking the question about the predictors of NIV failure is to ask which criteria one would use to intubate the asthmatic patient. This is not a consequence-free decision. It is possible to cause worsening bronchospasm, and to inadvertantly cause pneumothorax or worsening hyperinflation.

The following criteria are "consensus indications for intubation" listed in an article by Brenner et al (2009 - see Table 2). 

  • Progressive respiratory exhaustion (rising PaCO2)
  • Decreasing level of consciousness, altered sensorium
  • Severe hypoxemia
  • Silent chest
  • Respiratory arrest (or cardiac arrest)

Mechanical ventilation of the intubated asthmatic

There are several principles to abide by:

  • Use the largest tube possible: this will decrease the airway resistance and the peak airway pressures, not that hey are especially important. The machine will alarm less frequently.
  • Use lowest FiO2 to achieve SpO2 of 90-92%
  • Use a small tidal volume, 5-7ml/kg
  • Use a slow respiratory rate, 10-12 breaths per minute (or even less!)
  • Use a long expiratory time, with I:E ratio 1:3 or 1:4
  • Reset the pressure limits (i.e. ignore high peak airway pressures).  Given that the airway resistance will be high, with a maximised inspiratory flow rate one expects a high peak airway pressure, and cares little about it. One cares more about the plataeu pressure.
  • Use heavy sedation, because the respiratory acidosis will generate a powerful respiratory drive and you dont want this to interfere with your carefully planned ventilation strategy
  • Use neuromuscular blockade to defeat patient-ventilator dyssynchrony and to remove the contribution of respiratory muscles to the respiratory circuit resistance.
  • Minimise the duration of neuromuscular blockade: wean it as soon as possible; the combination of steroids and NMJ blockers leads to the hideous complication of acute necrotising myopathy. The most important predictor of this is the duration of paralysis.
  • Use a volume-control mode of ventilation: There is no evidence to help recommend one mode of ventilation over another. Oh's Manual recommends SIMV with volume support ventilation, because it features a square flow waveform. Because of this, the constant low flow rate generates a low-ish peak airway pressure, not that this matters very much. Pressure-controlled modes have the advantage of controllable peak pressures, but in asthma the high peak airway pressure is wholely due to the airway resistance, and the plateau pressure is typically modest.
  • Use minimal PEEP. One does not have a work of breathing to decrease in the sedated paralysed asthmatic, and so there is no need to overcome Auto-PEEP with intrinsic PEEP. Rather, one should instead make no effort to contribute to the existing Auto-PEEP. Back in the day, we used to ventilate patients with a PEEP of 0 (ZEEP). Now, it would appear that some small level of PEEP is actually beneficial - the theory is that it splints the spastic bronchi open, and thus actually improves the clearance of CO2 (as those little airways were otherwise going to collapse in expiration).
  • Keep the Pplat below 25cmH2o to prevent dynamic hyperinflation. With an arterial line, respiratory changes in pulse pressure variation can be obvious, and this will alert you to the increase in Auto-PEEP. Additionally, one can observe a number of waveform-plotted parameters:
    • End-tidal CO2 has a characteristic sawtooth pattern in dynamic hyperinflation.
    • The flow waveform fails to reach the zero line in dynamic hyperinflation.
    • An inspiratory hold manoeuvre can be performed to assess the plateau airway pressure (Pplat). This is a direct measure of alveolar hyperinflation. In general, this number should be below 25cm H2O. Empirical evidence demonstrates that this correlates with an end expiratory lung volume of around 20ml/kg (on top of the FRC!), which approaches total lung capacity. Beyond this level, complications due to dynamic hyperinflation will ensue.
    • An expiratory hold manoeuvre can be performed which measures auto-PEEP, but this manoeuvre tends to underestimate its true extent, as by the time expiration happens, many of the most bronchospastic airways have closed, and only the least bronchspastic airways remain open.
    • If one observes that dynamic hyperinflation is taking place, one may want to disconnect the patient from the ventilator, and manually decompress the chest - the "status asthmaticus hug". One will likely be rewarded with a nice increase in MAP and a nice fall in CVP.
  • Titrate PEEP to work of triggering: once the patient is triggering spontaneously on pressure support, you may titrate the CPAP to the minimum level at which the patient is able to flow-trigger the ventilator without undue effort. This reduces the work of breathing, and enhances the process of weaning.

The end result of all these measures is a ventilator monitor which looks something like this:

Servo-i monitor ventilating a severe asthmatic

Observe the waveforms. Classically, when one it trying to detect for dynamic hyperinflation, one is taught to lok for it in the flow waveform. However, expiratory flow is very poor, and the flow rate of the gas escaping  from the patient is probably somewhere well below 10L/min. As you can see, the scale of the flow graph in the image above is from -200 to +200 L/min. At this scale, the miniscule expiratory flow becomes impossible to detect. If the other waveforms were not available, one would not immediately shout "bronchospasm!" at this flow graphic. Thus, it is much better to use the volume over time waveform.  There is clearly an expiratoy flow limitation here; this modest 500ml tidal volume is taking about 4 seconds to escape. In fact, from this one can determine that the mean expiratory flow rate must be something like 7.5L/min. Anyway, in summary: look to the volume/time waveforms for evidence of dynamic hyperinflation. 

Tidal volume

Speaking of volumes and times; how does one safely select a tidal volume for a severe asthmatic? One needs to ask themselves two questions.

  • Why do they need a large volume?
  • What would you expect to happen with a large volume?

The first is a trick question. Nobody needs a large volume. 6-8ml/kg is going to be enough for the vast majority of the ICU population. As to the second question, the best answer is a diagram, representing a volume over time curve in somebody with severe airflow limitation:

effects of increasing the tidal volume on dynamic hyperinflation

So, in the form of words:

  • Expiration is a passive process
  • The forces driving expiration are weak and relatively fixed in their magnitude (i.e. elastic recoil of the lung and chest wall do not scale linearly with lung expansion; twice the volume does not produce twice the passive expiratory force)
  • With expiratory airflow limitation, there therefore a fixed maximum expiratory flow rate
  • With a fixed expiratory flow rate, a larger tidal volume will take longer to empty
  • Ergo,with large tidal volumes, a longer expiratory time will be required, lest you risk dynamic hyperinflation
  • This produces the need to decrease the respiratory rate.
  • As the result, the minute volume will not increase (though you've increased the tidal volume, you've had to decrease the respiratory rate), rendering the whole exercise completely pointless, to say nothing of the increased pneumothorax risk.

In summary, use lung-protective tidal volumes.

Inspiratory time and expiratory time

Though various highly reputable sources (Stather & Stewart, 2005; Leatherman et al, 2015;  Laher et al, 2018) might recommend "to shorten inspiratory time as much as possible", there is obviously a limit to this recommendation. For instance, it does not mean that in all status asthmaticus scenarios one should reduce the inspiratory time to the shortest possible duration permitted by the ventilator. Thinking along those lines might lead to absurd ventilator settings; for instance, the Siemens SERVO-i can deliver a maximum flow rate of  3.33L/sec, and so could theoretically blow a 500ml tidal volume over an I-time of 0.15 seconds. Obviously no sane person would ever leave the patient on those settings. So, there must be some safe (short) inspiratory time which everybody is comfortable with, and which still maximises expiratory time.

How long does the inspiratory time have to be, and for what scientific reason does it need to be longer than 0.15 seconds? There are two main reasons. For most conventional ventilation scenarios, a prolonged I-time allows the recruitment of lung units with longer time-constants, which favours oxygenation by increasing the available gas exchange surface, and by decreasing shunt by defeating the typical tendency of mechanically ventilated patients to develop atelectasis in their lung bases. These matters are less relevant in the context of severe status asthmaticus. For one, the lung units with the long time constants tend remain recruited throughout the respiratory cycle by autoPEEP. Atelectasis does not tend to be a major feature of severe acute asthma, and oxygenation is rarely the problem. The more important benefit of a longer inspiratory time in asthma is the tendency of short time constant units to fill quickly, taking much of the volume and therefore becoming the most hyperinflated during inspiration. A longer inspiratory time is therefore likely to result in a more even inflation among heterogeneous lung units, and therefore a reduced risk of pneumothorax. Sarnaik et al (2004) used this argument to support the use of a pressure-controlled mode of ventilation for asthamtic children. 

Another relevant benefit of a longer inspiratory time is the reduced flow rate. Using a "square" constant  flow pattern, one could deliver the 500ml volume over 0.15 seconds with a flow rate of around 200L/min, or over 1.0 seconds with a flow rate of 30L/min.  In severely bronchospastic highly resistant airways, flow rate will be directly related to the peak inspiratory pressure; the lower flow rate will produce much lower peak pressures, and fewer ventilator alarms.

The better question to ask is, how much good does it do to shorten inspiratory time to a minimum? Turns out, the benefit from it is probably minor, when compared to decreasing the respiratory rate. Tuxen & Lane (1987) found that changes to the respiratory rate and minute volume were by far the more effective. The ultimate benefit is from the increased expiratory time; removing extra breaths from a minute of ventilation increases the total expiratory time by a much large value than decreasing the inspiratory time of each breath from 1.0 to 0.5 seconds. 

In summary, the strategy of shortening the inspiratory time should be viewed as second fiddle to the strategy of decreasing the respiratory rate. It should be resorted to only in those scenarios where one cannot possibly decrease the respiratory rate any further, and but still wishes to have some additional minor advantage.  Another minor advantage is passing the CICM fellowship exam, where this topic comes up frequently, and where the official college answers (eg. in Question 27 from the second paper of 2012 and  Question 4 from the first paper of 2006 ) occasionally mention "minimise inspiratory time) as one of the strategies.  In order to score full marks, one would be expected to join the examiners in being inaccurate.

The use of PEEP

So. As with virtually everything in mechanical ventilation of asthma, this topic is somewhat controversial. The conventional teaching is to minimise the PEEP for these patients. In fact you're often ventilating them with zero PEEP (ZEEP). The rationale for this is:

  • In terms of getting all the beneficial PEEP effects (eg. increased FRC, better oxygenation), there is no need for any additional ventilator-generated PEEP because the patient already has plenty of intrinsic PEEP.
  • Oxygenation is not the issue in any case.
  • The gradient between intrathoracic pressure (intrinsic PEEP) and extrathoracic pressure (ventilator-generated PEEP) is what drives expiratory flow, and therefore surely we would want to maximise this gradient to promote expiratory CO2 clearance

There is also the erroneous belief that the added ventilator-generated PEEP might somehow "stack" with the intrinsic PEEP, increasing the total PEEP by some sort of weird additive mechanism. Clearly, this is wrong, as it defies logic. 

Anyway. There is also a rationale for having some PEEP:

  • Intrinsic PEEP is generated by the closure of small airways in expiration
  • These small airways close because:
    • Parenchymal lung pressure (intrinsic PEEP) is higher than internal bronchial expiratory pressure (ventilator-generated PEEP)
    • Expiratory airflow is too rapid (Rodarte et al, 1975)
  • Thus:
    • With ZEEP, small airways will close completely, and even though the intrathoracic-extrathoracic gradient is higher, no airflow will take place anyway because that gas is well and truly trapped.
    • Therefore, keeping some pressure in the bronchi (using some small amount of PEEP) should keep the small airways open during expiration, and actually promote airflow
    • Keeping the expiratory airflow on the slower side (by artificially reducing the intrathoracic-extrathoracic pressure gradient) should also keep these small airways from collapsing.

So, some sort of careful minimalist PEEP is probably either not harmful, or actually helpful. In fact, as long as the ventilator-generated PEEP is not higher than the intrinsic PEEP, there should be no harmful effects.

This is not exactly a highly evolved well-investigated scientific territory. We have case reports and expert opinion to guide us. For a representative example, Golchin et al (2018) had used a small amount of PEEP in their asthmatic, and demonstrated an improvement in the degree of dynamic hyperinflation (in terms of haemodynamics and ventilator measurements) but this was not even a case report, but a poster presentation from the International  Conference of the American Thoracic Society, barely meeting the definition of a peer-reviewed publication. That's the level of evidence we are dealing with here. It is probably also possible to extrapolate some of the findings from the COPD literature, because surely bronchospasm is bronchospasm?... Kondili et al (2004) found that some PEEP (5 or 10) produced a more uniform pattern of lung emptying in patients with COPD, whereas ZEEP produced a higher respiratory resistance and time constant. The same was demonstrated by Tuxen et al (1989), who tested asthmatics at PEEP of 5, 10 and 15. The investigators found that, at any given respiratory rate, the increase in PEEP produced an improvement in gas trapping. However (probably because they were using monstrous pre-ARDSNet tidal volumes) the increase in FRC with extra PEEP exceeded the decrease in gas trapping, i.e. the patient was now hyperinflated because of the insane ventilation strategy rather than because of the asthma. "PEEP produced significant but unnecessary improvements in arterial oxygenation and potentially dangerous increases in lung volumes and airway and intrathoracic pressures", Tuxen et al concluded unselfconsciously.

Without the support of published evidence, the author reluctantly finds himself pretending to be a mechanical ventilation expert.  So, what recommendation can be made with a straight face, regarding the use of PEEP in severe asthma? Perhaps the following:

  • PEEP is not essential in the mechanical ventilation of a sedated paralysed asthma patient
  • The use of zero PEEP in asthma is safe (in the sense that it will not produce the complications of low FRC).
  • The use of a small amount of PEEP (under 10 cmH2O) may be beneficial.
  • It is probably impossible to prospectively detect patients who will benefit from a small amount of PEEP.
  • If zero PEEP is used, and the patient has significant evidence of dynamic hyperinflation (determined by ventilator manoeuvres and haemodynamic assessment), you can trial a careful titration of PEEP up from 0, for example; if the patient is going to benefit from the extra PEEP, the "significant evidence" of dynamic hyperinflation should become less significant. The endpoint should probably be CO2 clearance and pulse pressure variation.

This "responsiveness" to extrinsic PEEP is going to change dynamically over the course of time, perhaps over the timeframe of minutes (eg. after every neb). Fortunately, if the intrinsic PEEP increases, the extrinsic PEEP is not going to cause much of a problem, as it may decrease the airway collapse (and unless comically huge tidal volumes are used, you should not see any problems with this). Alternatively, if the intrinsic PEEP decreases, the extrinisic PEEP will not going to cause problems either, because you're probably using a very low level of PEEP (i.e. under 10 cm H2O).

Mucolytics

Tenacious mucus plugging is a major problem and historically people have viewed mucolytics +/- bronchoscopy as either a major curative strategy or a end-of-the-line last ditch rescue therapy for intubated severe asthma patients. A representative article from the heyday of this strategy is Henke et al (1996), whose team tended to give 3ml of an N-acetylcysteine/salbutamol mixture into each lobe of the lung via a bronchoscope and then suctioned the resulting mucus. 

The options for mucolytic agent are

  • Recombinant human DNase (rhDNase)
  • Hypertonic saline
  • N-acetylcysteine

This practice is far from dead. A more recent survey of British intensivists found that "recombinant human DNase (rhDNase) does get administered by 63% of clinicians, with 54% and 19% that administer hypertonic saline or N-acetylcysteine, respectively" (Snoek et al, 2015). Case reports with miraculous rescues exist (eg. Hull et al, 2010).

The largest part of the literature on this topic comes in the from of observational studies and case reports. The rest is evidence extrapolated from cystic fibrosis patients, burns patients, surgical patients and other non-asthma territories.  For these reasons, most authors do not recommend mucolytics. In their chapter (Ch 5, Acute Exacerbations of Asthma) for Pulmonary Emergencies (2016), Bhakta and Lazarus placed mucolytics into the "Therapies without supporting evidence" table. Irwin and Rippe (p 708, section 4) also could not recommend either rhDNAse or N-acetylcysteine. In fact, even in cystic fibrosis the benefits of rhDNAse were not statistically significant (seems antibiotics and chest physiotherapy did all the work).  The most recent consensus guidelines (Expert Panel Report 3, 2007) do not support the routine use of mucolytics.

ECMO 

When all else fails, patients who are dying from this reversible condition should be offered ECMO wherever it is available. A publication from 2003 details a series of case reports, which support the use of ECMO in near-fatal asthma. If hypercapnea is what ails you, CO2 removal alone by ECCOR is also an option. Obviously, owing to the extreme potential complications, and the violently invasive nature of this treatment, it should probably be reserved for patients in whom all other management strategies have failed.

References

Oh's Intensive Care manual: Chapter 35   (pp. 401) Acute  severe  asthma by David  V  Tuxen  and  Matthew  T  Naughton.

Stow, Peter J., et al. "Improved outcomes from acute severe asthma in Australian intensive care units (1996–2003)." Thorax 62.10 (2007): 842-847.

Sekiya, Kiyoshi, et al. "Clinical evaluation of severe asthma attacks requiring tracheal intubation and mechanical ventilation." Allergology International 58 (2009): 289-294.

Sandford, Andrew J., et al. "Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity." Journal of Allergy and Clinical Immunology 106.1 (2000): 135-140.

McFadden Jr, E. R. "Acute severe asthma." American journal of respiratory and critical care medicine 168.7 (2003): 740-759.

Bousquet, Jean, et al. "Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma." Journal of Allergy and Clinical Immunology126.5 (2010): 926-938.

Perrin, Kyle, et al. "Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma." Thorax 66.11 (2011): 937-941.

Rodrigo, Gustavo J., et al. "Effects of Short-term 28% and 100% Oxygen on Paco2 and Peak Expiratory Flow Rate in Acute AsthmaA Randomized Trial."CHEST Journal 124.4 (2003): 1312-1317.

Sellers, W. F. S. "Inhaled and intravenous treatment in acute severe and life-threatening asthma." British journal of anaesthesia 110.2 (2013): 183-190.

Cates, C. J., E. J. Welsh, and B. H. Rowe. "Holding chambers (spacers) versus nebulisers for delivery of beta-agonist relievers in the treatment of an asthma attack." (2013).

Teoh, Laurel, et al. "Anticholinergic therapy for acute asthma in children."Cochrane Database Syst Rev 4 (2012).

Coupe, M. O., et al. "Nebulised adrenaline in acute severe asthma: comparison with salbutamol.European journal of respiratory diseases 71.4 (1987): 227-232.

Albertson, T. E., et al. "Pharmacotherapy of critical asthma syndrome: current and emerging therapies." Clinical reviews in allergy & immunology (2014): 1-24.

Powell, Colin, et al. "Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial." The Lancet Respiratory Medicine 1.4 (2013): 301-308.

Shan, Zhilei, et al. "Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta-analysis."Respiratory medicine 107.3 (2013): 321-330.

Wigmore, T., and E. Stachowski. "A review of the use of heliox in the critically ill." Critical Care and Resuscitation 8.1 (2006): 64.

Rodrigo, G., et al. "Heliox for nonintubated acute asthma patients." Cochrane Database Syst Rev 4 (2006).

Jat, Kana R., and Deepak Chawla. "Ketamine for management of acute exacerbations of asthma in children." Cochrane Database of Systematic Reviews 11 (2012).

Howton, Joseph C., et al. "Randomized, double-blind, placebo-controlled trial of intravenous ketamine in acute asthma." Annals of emergency medicine 27.2 (1996): 170-175.

Vaschetto, R., et al. "Inhalational anesthetics in acute severe asthma." Current drug targets 10.9 (2009): 826-832.

Lobaz, S., and M. Carey. "Rescue of acute refractory hypercapnia and acidosis secondary to life-threatening asthma with extracorporeal carbon dioxide removal (ECCO2R)." JICS 12.2 (2011): 140-142.

Leiba, Adi, et al. "Early administration of extracorporeal life support for near fatal asthma." IMAJ-RAMAT GAN- 5.8 (2003): 600-602.

Samaria, J. K. "Role Of Niv In Acute Respiratory Failure Due To Asthma: Effectiveness And Predictors Of Failure." Am J Respir Crit Care Med 183 (2011): A1365.

Op't Holt, Timothy B. "Additional Evidence to Support the Use of Noninvasive Ventilation in Asthma Exacerbation." Respiratory care 58.2 (2013): 380-382.

Lim, Wei Jie, et al. "Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma." The Cochrane Library Published Online: 12 DEC 2012

Gupta, Dheeraj, et al. "A prospective randomized controlled trial on the efficacy of noninvasive ventilation in severe acute asthma." Respiratory care 55.5 (2010): 536-543.

Williams, Trevor J., et al. "Risk factors for morbidity in mechanically ventilated patients with acute severe asthma." The American review of respiratory disease146.3 (1992): 607-615.

Lacomis, David, Thomas W. Smith, and David A. Chad. "Acute myopathy and neuropathy in status asthmaticus: case report and literature review." Muscle & nerve 16.1 (1993): 84-90.

Hermans, Greet, et al. "Clinical review: critical illness polyneuropathy and myopathy." Crit Care 12.6 (2008): 238.

Green, Elyce, Paras Jain, and Maree Bernoth. "Noninvasive ventilation for acute exacerbations of asthma: A systematic review of the literature." Australian Critical Care (2017).

SAMARIA, JAI K., and Satyadeo Chaubey. "Role Of NIV In Acute Respiratory Failure Due To Asthma: Effectiveness And Predictors Of Failure." A34. MANAGEMENT OF ASTHMA, RHINITIS, AND SINUSITIS. American Thoracic Society, 2011. A1365-A1365.

Henke, Craig A., Marshall Hertz, and Paul Gustafson. "Combined bronchoscopy and mucolytic therapy for patients with severe refractory status asthmaticus on mechanical ventilation: A case report and review of the literature." Critical care medicine 22.11 (1994): 1880-1883.

Snoek, Aarjan Peter, and Joe Brierley. "Mucolytics for intubated asthmatic children: a national survey of United kingdom paediatric intensive care consultants." Critical care research and practice 2015 (2015).

Hull, James HK, et al. "Nebulised DNase in the treatment of life threatening asthma." Resuscitation 74.1 (2007): 175-177.

van der Hoeven, Sophia M., et al. "Preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated intensive care unit patients (NEBULAE): study protocol for a randomized controlled trial.Trials 16.1 (2015): 389.

Busse, W. W., et al. "Expert panel report 3: Guidelines for the diagnosis and management of asthma." Washington, DC: US Department of Health and Human Services, National Heart Lung and Blood Institute (2007): 1-417.

Stather, David R., and Thomas E. Stewart. "Clinical review: mechanical ventilation in severe asthma." Critical Care 9.6 (2005): 581.

Leatherman, James. "Mechanical ventilation for severe asthma." Chest 147.6 (2015): 1671-1680.https://www.atsjournals.org/doi/abs/10.1164/ajrccm/136.4.872

Laher, Abdullah E., and Sean K. Buchanan. "Mechanically ventilating the severe asthmatic." Journal of intensive care medicine 33.9 (2018): 491-501.

Tuxen, David V., and Susan Lane. "The effects of ventilatory pattern on hyperinflation, airway pressures, and circulation in mechanical ventilation of patients with severe air-flow obstruction." American Review of Respiratory Disease 136.4 (1987): 872-879.

Tuxen, David V. "Detrimental effects of positive end-expiratory pressure during controlled mechanical ventilation of patients with severe airflow obstruction." Am Rev Respir Dis 140.1 (1989): 5-9.

Sarnaik, Ashok P., et al. "Pressure-controlled ventilation in children with severe status asthmaticus." Pediatric Critical Care Medicine 5.2 (2004): 133-138.

Oddo, Mauro, et al. "Management of mechanical ventilation in acute severe asthma: practical aspects." Intensive care medicine 32.4 (2006): 501-510.

Golchin, A., K. Hachey, and A. Khan. "Is There a Role of Applied PEEP (PEEPe) in Controlled Mechanically Ventilated Severe Asthma Exacerbations?." C52. CRITICAL CARE CASE REPORTS: GOOD VIBRATIONS-MECHANICAL VENTILATION FROM NIV TO ECMO. American Thoracic Society, 2018. A5270-A5270.

Smith, THOMAS C., and JOHN J. Marini. "Impact of PEEP on lung mechanics and work of breathing in severe airflow obstruction." Journal of Applied Physiology 65.4 (1988): 1488-1499.

Kondili, Eumorfia, et al. "Pattern of lung emptying and expiratory resistance in mechanically ventilated patients with chronic obstructive pulmonary disease." Intensive care medicine 30.7 (2004): 1311-1318.

Browne, Gary J., et al. "Randomised trial of intravenous salbutamol in early management of acute severe asthma in children." The Lancet 349.9048 (1997): 301-305.

Tobin, A. "Intravenous salbutamol: too much of a good thing?." Critical Care and Resuscitation 7.2 (2005): 119-127.

Salmeron, Sergio, et al. "Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study." American journal of respiratory and critical care medicine 149.6 (1994): 1466-1470.

Aralihond, A., et al. "Treating acute severe asthma attacks in children: using aminophylline.Breathe 16.4 (2020).

Yung, Michael, and Mike South. "Randomised controlled trial of aminophylline for severe acute asthma." Archives of Disease in Childhood 79.5 (1998): 405.

Carlsson, Jenny A., and Hannah K. Bayes. "Acute severe asthma in adults.Medicine 48.5 (2020): 297-302.

Littenberg, Benjamin. "Aminophylline treatment in severe, acute asthma: a meta-analysis." JAMA 259.11 (1988): 1678-1684.

Baldwin, David R., et al. "Comparison of the effects of salbutamol and adrenaline on airway smooth muscle contractility in vitro and on bronchial reactivity in vivo." Thorax 49.11 (1994): 1103.

Costello, Jonathan, and Marten Howes. "Nebulised magnesium in asthma.Emergency Medicine Journal: EMJ 21.5 (2004): 586.

Lew, Alicia, et al. "Volatile anesthetic agents for life‐threatening pediatric asthma: A multicenter retrospective cohort study and narrative review." Pediatric Anesthesia 31.12 (2021): 1340-1349.

Turner, David A., et al. "Isoflurane for life-threatening bronchospasm: a 15-year single-center experience." Respiratory care 57.11 (2012): 1857-1864.